Skip to main content

Correction to: Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations

The Original Article was published on 07 March 2018

Correction to: BMC Cancer (2018) 18:264

https://doi.org/10.1186/s12885-018-4050-1

Following publication of the original article [1], the authors reported errors in Fig. 3, Fig. 14a, Fig. 18, Fig. 19b, Additional file 3 and Additional file 7. The title of Additional file 9 contains a typing error and is correctly given below.

Fig. 3
figure 1

Most active compound (IC50 = 0.2) mapped to all the features

Fig. 14
figure 2

a Molecular interaction between the reference- protein (purple). Green dotted lines indicate the hydrogen bonds. The residues are represented in orange stick model

Fig. 18
figure 3

Binding mode assessment of compounds. The co-crystal is represented in gray, reference is denoted in green and the Hit in orange. All the three follow the same pattern

Fig. 19
figure 4

b Intermolecular interactions between the ligand and the protein. Green dotted lines represent the hydrogen bonds. The protein residues are indicated in cyan

The following typing errors have been identified:

Page no

Column/paragraph

line

Present word

Change to

1

Abstract/results

2

of

above

2

1/2

2

Cyclic

Cyclin

2

2/1

3

VEGFR

VEGFR-2

12

2/1

3

prognosis

progression

12

2/1

10

form

from

19

Above conclusions

4

Cyc919

Cys919

10

2/1

13

20 ps

20 ns

10

2/1

15

25 ps

25 ns

13

2/1

6

four

five

Table 5/ reference

van der Waals interactions

asn900leu1044

Asn900, Ile1044

Fig 10

30 ps

30 ns

Fig 16

refrence

reference

Further to this, in Table 1, HyP is incorrectly represented as HyB and Hy-Ali as HyAli/HY-Ali. The corrected Table 1 can be found here.

Table 2 Table 1

These corrections do not alter the context of the manuscript.

Reference

  1. Rampogu S, et al. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. BMC Cancer. 2018;18:264. https://doi.org/10.1186/s12885-018-4050-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keun Woo Lee.

Supplementary information

Additional file 3.

2D interaction representation of the reference compound and 4AG8. Detailed molecular interactions of the reference compound.

Additional file 7.

2D interaction representation of the reference compound and 1URW. Molecular interaction details of the reference compound.

Additional file 9.

Active sites comparison. Comparison of the active site residues of 4AG8 and 1URW.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rampogu, S., Baek, A., Zeb, A. et al. Correction to: Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. BMC Cancer 19, 1249 (2019). https://doi.org/10.1186/s12885-019-6378-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-019-6378-6